ChemoMetec Raises FY26/27 Revenue and EBITDA Guidance
ChemoMetec now expects FY26/27 revenue of DKK 560—590M (from DKK 545—575M) and EBITDA of DKK 330—345M (from DKK 300—315M).
ChemoMetec A/S now expects FY26/27 revenue of DKK 560—590M, up from DKK 545—575M, and EBITDA of DKK 330—345M versus DKK 300—315M. The company cited stronger NC-203 demand and lower costs. Material Details Context by AI Analyst This is an early-cycle confirmation of improving momentum, with demand for NC-203 and cos…